February 26, 2024
As the calendar flips to 2024, we at SeQure Dx find ourselves at an exhilarating crossroads. With a year of groundbreaking achievements behind us and the horizon filled with promising opportunities, we’re eager to share our journey and the future we’re passionately working towards.
January 23, 2024
Synthego and SeQure Dx Partner to Provide Comprehensive Off-Target Analysis Services for CRISPR-Based Therapeutics Developers
Synthego, a leading provider of genome engineering solutions, and SeQure Dx, a company focused on off-target analysis for preclinical and clinical gene modification customers, have announced a strategic partnership to provide CRISPR-based therapeutics developers with comprehensive off-target editing analytical services that include best-in-class technology and turn-key end-to-end development solutions.
November 30, 2023
KromaTiD and SeQure Dx enter partnership agreement to offer comprehensive, IND-enabling gene editing services supporting cell and gene therapy research
KromaTiD and SeQure Dx announced today a partnership to market a comprehensive and integrated analysis of off-target gene editing in support of cell and gene therapy research, Investigational New Drug (IND) applications and drug product development.
May 03, 2023
SeQure Dx to present at American Society of Gene and Cell Therapy (ASGCT) on the importance of incorporating population heterogeneity evaluation into gene editing and cell therapy off-target analyses
SeQure Dx, Inc, a leading genomics intelligence company, announced today it will present new data at the 2023 American Society of Gene and Cell Therapy Annual Meeting from May 16 – 20 in Los Angeles.
November 16, 2022
SeQure Dx emerges from stealth mode to fulfill the promise of on-target gene editing therapies for biopharma partners, physicians, and patients
Building on Dr. J. Keith Joung’s ONE-seq platform, SeQure Dx has developed a portfolio of assays and data solutions to find, assess, and manage off-target risks from discovery to clinical development to patient impact.
August 03, 2021
Patented technology addresses emerging need for personalized diagnostics that assess the risks of gene-editing therapies